Outsourcing

Articles

The glass and chemical provider will expand its synthetic pharmaceutical intermediate and API production capacity at its plant in Chiba, Japan.

AGC to Expand Chemical and API Capacity

The acquisition will place Cambrex into the finished dosage form CDMO market.

Cambrex to Acquire Halo Pharma for $425 Million

CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.

Novartis, CELLforCURE Partner to Manufacture CAR-T Therapies

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

Fifteen Years of Progress: Biopharmaceutical Industry Survey Results

Agnes Shanley is senior editor of Pharmaceutical Technology.

Vendors are offering template-based models and direct data-filing services to help smaller companies meet imminent deadlines.

Serialization: Scaling Down for the Final Stretch

Minakem’s facility in Belgium enhances capacity to scale production of highly potent ingredients for small to full GMP batches.

Minakem Opens New High Containment Facility

The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.

Canada OKs Samsung BioLogics’ mAb Drug Substance Plant

WuXi STA supported the development of hepatitis drug through marketing authorization holder pilot program.

CFDA Approves Drug Developed with CDMO Support

Recipharm adds inhalation drug manufacturing capacity with the acquisition of Sanofi’s Holmes Chapel, UK site.

Recipharm Acquires Respiratory Drug Site

Cambrex expands its generic API research and development capabilities at its Milan, Italy site.

Contract Manufacturing Services